LAPORTE KATHLEEN 4
4 · Bolt Biotherapeutics, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Bolt Biotherapeutics Director Kathleen LaPorte Receives 5,000-Share Award
What Happened
Kathleen LaPorte, a director of Bolt Biotherapeutics, was granted a derivative award for 5,000 shares on June 10, 2026. The Form 4 lists the acquisition price as $0.00, indicating no cash was paid at grant; the transaction is recorded as an award/grant (derivative), not an open-market purchase or sale.
Key Details
- Transaction date: June 10, 2026; Form 4 filed June 11, 2026 (timely filing).
- Transaction type/code: A — Grant/Award (derivative).
- Shares involved: 5,000 shares granted at $0.00; immediate reported value $0.
- Vesting note: The award vests on the earlier of June 9, 2027 or the day before the next annual meeting, subject to continuous service; it vests in full upon a change in control.
- Shares owned after transaction: not specified in the filing.
Context
This is a compensatory grant (commonly RSUs or similar) rather than a purchase, so it reflects company compensation practices rather than an out-of-pocket investment by the director. The vesting schedule ties the award to continued service and provides acceleration on a change in control. The prompt filing the next day indicates no late-reporting issue.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-10+5,000→ 5,000 totalExercise: $4.43Exp: 2036-06-09→ Common Stock (5,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.